Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says
- Top-10 investor said to have concerns on costs, returns
- Indirect backing for $62 billion deal secured in June
People wait at the reception hall of Takeda Pharmaceutical Co.'s global headquarters in Tokyo.
Photographer: Kentaro Takahashi/BloombergOne of the top 10 shareholders in Japanese drugmaker Takeda Pharmaceutical Co. is “skeptical” on the value that will be created from the group’s $62 billion takeover of rare disease specialist Shire Plc, the Sunday Times reported, citing the unidentified investor.
The deal, the biggest in Osaka-based Takeda’s history, has already faced opposition from a group of investors that calls itself “Thinking About Takeda’s Future.” It comprises former Takeda employees and shareholders who together own about 1 percent of the company’s stock and who oppose Takeda’s expansion. Concerns have also been raised about Takeda’s debt after the acquisition, which includes a $31 billion loan.